Valhalla, NYNCT07013565Now EnrollingIRB Ready

Anaplastic Large Cell Lymphoma, ALK-Positive Clinical Trial in Valhalla, NY

Access cutting-edge anaplastic large cell lymphoma, alk-positive treatment through this clinical trial at a research site in Valhalla. Study-provided care at no cost to qualified participants.

Sponsored by New York Medical College

Quick Self-Assessment

See if you qualify for this Valhalla location

Preparing your pre-screening questions…

Expert Care in Valhalla

Access anaplastic large cell lymphoma, alk-positive specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related anaplastic large cell lymphoma, alk-positive treatment provided free

Apply for This Valhalla Location

Check if you qualify for this anaplastic large cell lymphoma, alk-positive clinical trial in Valhalla, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Valhalla

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Valhalla site if eligible
  4. 4Begin participation

About This Anaplastic Large Cell Lymphoma, ALK-Positive Study in Valhalla

Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival. This clinical trial will investigate if a new FDA approved medication called Nivolumab (NIVO) (which is a checkpoint blockade immunotherapy) combined with chemotherapy based on the patients risk status to get the patient into the best response possible. Then patients will receive lower doses of chemoimmunotherapy and allogeneic stem cell transplantation (stem cells from another person). The investigators this this new treatment will improve survival rates in this high-risk population of patients.

Sponsor: New York Medical College

Who Can Participate

Inclusion Criteria

Patients must weigh ≥10 kilograms at the time of study enrollment.
Patients with relapsed or refractory histologically or cytologically proven ALK-positive anaplastic large cell lymphoma meeting Low or High Risk Criteria: Low Risk Cohort (LR cohort):
Any patient with FIRST RELAPSE \> ONE YEAR from initial diagnosis of de novo ALK+ ALCL,
Common histology,
CD3 negative, AND
No prior exposure to vinblastine (VBL). High-Risk Cohort (HR cohort):
Any patient with RELAPSED OR PROGRESSIVE DISEASE less than ONE YEAR from initial diagnosis of de novo ALK+ ALCL,
Small cell/histiocytic histology,
CD3 positive (homogeneous staining of CD3 positive T-cells)
Patients must have adequate organ function.
Patients must have performance status 60 or above.

Exclusion Criteria

ALK-NEGATIVE anaplastic large cell lymphoma.
Patients with active leptomeningeal disease (lymphoma cells in CSF).
Previous treatment with vinblastine (only in patients in the LR cohort).
Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarche.
Lactating females unless they have agreed not to breastfeed their infants.
Patients with Down syndrome.
Any patient with uncontrolled infection prior to study entry.
Any patient known to have primary or acquired immunodeficiency and/or prior solid organ transplant.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Valhalla?

Yes, this clinical trial (NCT07013565) has an active research site in Valhalla, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Anaplastic Large Cell Lymphoma, ALK-Positive Treatment Options in Valhalla, NY

If you're searching for anaplastic large cell lymphoma, alk-positive treatment options in Valhalla, NY, this clinical trial (NCT07013565) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Valhalla research site is actively enrolling participants for this clinical trial. You'll receive care from experienced anaplastic large cell lymphoma, alk-positive specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all anaplastic large cell lymphoma, alk-positive clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Valhalla, NY

See all lymphoma clinical trials recruiting in Valhalla — not just this study.

Browse Lymphoma Trials in Valhalla →

Browse More Trials by Condition

Lymphoma TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Valhalla?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Valhalla, NY